Castro MMG, Molina CA, Martínez MJM, Gallardo CVE, Liceaga CMG

Language: Spanish
References: 22
Page: 406-410
PDF size: 237.17 Kb.

ABSTRACT

The liver injury secondary to drug hepatotoxicity is rare. Its incidence is 1 case per 10.000 to 100.000 recipes, which represents 0.1 to 3% of hospital admissions, but still in our midst is a underdiagnosed condition. Since most drugs are metabolized in the liver, inducing liver damage is a potential complication when treating patients with «any drug.» The diagnosis of this condition requires a high index of clinical suspicion. Since its identification is difficult should be suspected in any patient with liver dysfunction and a history of drug ingestion. A case of a patient who was with amoxicillin-clavulanate hepatotoxicity and review the literature on this.

REFERENCES

1. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-55.

2. Hartleb M, Biernat L, Kochel A. Drug-induced liver damage a three-year study of patients from one gastroenterological department. Med Sci Monit 2002;8:CR292-296.

3. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem ResToxicol 2001;14:611-650.

4. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2003;349:474-485.

5. Lee WM. Drug-induced acute liver failure in the United State 2005: results from the U.S. Acute Liver Failure Study Group. FDA-PhRMA-AASLD Hepatotoxicity Steering Committee meeting 28 January 2005. www.fda.gov/cder/livertox/presentations2005/William_Lee.ppt

6. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects: review of the literature. Eur J Med Res 2001;6:139-149.

7. Iravani A, Richard GA. Amoxicillin-clavulanic acid versus cefaclor in the treatment of urina- ry tract infections and their effects on the urogenital and rectal flora. Antimicrob Agents Chemother, 1986;29: 107-11.

8. Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995;23:278-282.

9. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut 1992;33:368-371.

10. Garcia LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996;156:1327-1332.

11. Fontana RS, Greenson JB, Lee W. Acute Liver Failure Due To Amoxicillin and Amoxicillin/Clavulanate. Digestive Diseases & Sciences 2005; 50(10):1785-1790.

12. Lee WM. Drug-Induced Hepatotoxicity. N Engl J Med 2003;349:474-485.

13. Murray KF, Hadzic N, Wirth Z, et al. Drug-related Hepatotoxicity and Acute Liver Failure. JPGN 2008;47:395-405.

14. Chawla A, Kahn E, Yunis EJ, et al. Rapidly progressive cholestasis: an unusual reaction to amoxicillin-clavulanic acid therapy in a child. J Pediatr 2000;136:121-123.

15. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978.

16. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994;271:992-998.

17. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310.

18. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-130.

19. Hautekeete ML, Brenard R, Horsmans Y, et al. Liver injury related to amoxicillin-clavulanic acid: interlobular bileduct lesions and extrahepatic manifestations. J Hepatol 1995;22:71-77.

20. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006;44:850-856.

21. Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin. Gastroenterol 2003;19:216-231.

22. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002;36:525-531.